Insulin and leptin as potential cognitive enhancers in metabolic disorders and Alzheimer's disease

Neuropharmacology. 2020 Jul:171:108115. doi: 10.1016/j.neuropharm.2020.108115. Epub 2020 Apr 25.

Abstract

Recent clinical and epidemiological observations point to a correlation between disorders of energy metabolism, such as obesity and diabetes, and cognitive decline and dementia. Many studies indicate that these age-related conditions closely interact with each other, but the underlying molecular and physiological mechanisms for such correlations are largely unknown. Insulin and leptin, hormones classically implicated in diabetes and obesity, are gaining increasing attention for their participation in cognitive processes and memory. Disrupted signaling by those hormones is associated with impaired brain function. The current review discusses how restoration of insulin and leptin signaling in the brain may attenuate neuronal damage and promote cognition. We further discuss potential therapeutic approaches involving the use of insulin and leptin as cognitive enhancers in the context of metabolic disorders and Alzheimer's disease. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

Keywords: Alzheimer's disease; Cognition; Diabetes; Insulin; Leptin; Neuroprotection; Obesity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / psychology*
  • Animals
  • Biomarkers
  • Energy Metabolism / drug effects
  • Humans
  • Insulin / therapeutic use*
  • Leptin / therapeutic use*
  • Metabolic Diseases / drug therapy*
  • Metabolic Diseases / psychology*
  • Nootropic Agents / pharmacology*

Substances

  • Biomarkers
  • Insulin
  • Leptin
  • Nootropic Agents

Grants and funding